The retatrutide onset after tirzepatide transition sets realistic timeline expectations
Once you select a new day, maintain that schedule consistently going forward
For weight management , semaglutide (Wegovy) is approved by the MHRA and has received a positive NICE technology appraisal recommendation for use in adults with obesity or overweight with weight-related comorbidities, subject to eligibility criteria
Retatrutide isnt licensed in the UK, so any product sold online is unlicensed
The standard starting dose is 20 units on an insulin syringe (0.2 mL)
However, studies have reported side effects like gastrointestinal discomfort, nutritional deficiencies due to poor eating, muscle loss, and weight regain after treatments end